|
||
Original Article |
goff{at}cuccfa.ccc.columbia.edu
| Abstract |
|---|
|
|
|---|
Key Words: retinal angiogenesis oxidative stress DNA damage nonreceptor tyrosine kinase vascular endothelial growth factor
The mechanism by which oxygen levels elicit changes in VEGF expression is poorly understood. However, reactive oxygen intermediates have been implicated in the pathogenesis of ROP 17. The administration of antioxidants to mice exposed to a hyperoxia regimen prevented the development of retinopathy 18. In addition, there is evidence that HIF-1 binds to DNA damaged by oxidation and may affect the repair rate of oxidation-induced strand breaks 19.
c-Abl is a protooncogenic nonreceptor tyrosine kinase with an NH2-terminal domain that is homologous to Src family members and a unique COOH-terminal region 20. Mutant forms of c-abl have been characterized in leukemias of mice and humans 21. There are two isoforms of c-abl that differ at the NH2-terminal sequences due to alternate 5' exons 202223. The c-abl protein is ubiquitously expressed and localizes to the cytoplasm and nucleus where it has distinct roles 2023. Effects of c-abl on the cell cycle, apoptosis, and cellular transformation depend on protein interactions with its various functional domains: Src homology (SH)3, SH2, tyrosine kinase domain, proline-rich binding sites, and actin binding domain. c-Abl participates in the signal transduction pathways induced by growth factors 24, integrins 25, and genotoxic stresses such as ionizing radiation and hydrogen peroxide 26272829. c-Abl tyrosine kinase activity may be enhanced by Src kinases that directly phosphorylate the kinase domain of c-abl 24. Both VEGF and ET-1 receptor signaling require c-Src–dependent pathways 1630, and these cytokines have been implicated in the pathogenesis of oxygen-induced neovascularization. Because c-abl participates in the cellular response to oxidation-induced DNA damage and in Src kinase–dependent signaling pathways, we hypothesized that c-abl may be involved in the angiogenic response to hyperoxia.
The in vivo requirement of c-abl for hyperoxia-induced neovascularization was investigated using an established mouse model for ROP and mice carrying knockout mutations of the c-abl gene 931. We report that, unlike wild-type (wt) control animals, mice homozygous for a c-abl null mutation do not develop neovascular retinopathy in response to hyperoxia. To determine if retinal VEGF and ET-1 expression in response to hyperoxia are aberrantly regulated, their mRNA levels were analyzed using RNase protection assays. We observe that ET-1 mRNA levels in retinas of wt and homozygous c-abl null animals do not differ, and exposure to the hyperoxia regimen does not alter ET-1 mRNA levels in either wt or c-abl null animals. As reported by others, we find that retinal VEGF mRNA levels in wt animals change in response to hyperoxia. However, VEGF mRNA levels remained unchanged in oxygen-exposed c-abl null mice compared with control animals.
Mouse Model of ROP.
To study the retinal vascular pattern, fluorescein angiography was performed as described previously 9. Animals were given a lethal dose of sodium pentobarbital and a median sternotomy was performed. The left ventricle was perfused with fluorescein-conjugated dextran 34. Eyes were enucleated and placed in 4% paraformaldehyde PBS for 4 to 24 h. Retinas were dissected and flat mounted. Retinal whole-mounts were visualized using fluorescent microscopy. Two independent observers scored the vasoproliferative response in a masked fashion using the retinopathy scoring system 33. Data were subject to analysis of variance using the Mann-Whitney test to test for differences among the total retinopathy scores of individual groups.
To quantify the neovascular response, nuclei of new blood vessels were periodic acid-Schiff (PAS) stained and counted 9. Mice were killed on P17–20 and perfused with 4% paraformaldehyde in PBS. Frozen tissue sections (8–9-µm thick) from mid-peripheral retina were prepared and stained with PAS and hematoxylin. A minimum of six sections from both eyes per animal was prepared for analysis. Vascular cell nuclei that were present beyond the inner limiting membrane into the vitreous were counted in a masked fashion using light microscopy. The number of vascular nuclei for each eye was averaged. Student t tests were used to test for differences between hyperoxia and control treatment groups.
Corneal Angiogenesis Assay.
RNase Protection Assay for ET-1 and VEGF.
Single-stranded antisense [32P]RNA probes were prepared from ET-1 and VEGF cDNA cloned fragments using the pBluescript plasmids described above as templates for transcription by T7 and T3 polymerases, respectively. A mouse actin riboprobe (304 nt) was prepared in parallel using pTRI-β-actin as a template (Ambion) and T7 polymerase. The full-length ET-1 and VEGF riboprobes are 584 and 615 nt, respectively. Transcription reactions proceeded according to instructions provided in the MAXIscript transcription kits (Ambion). For RNase Protection assays, ET-1, VEGF, and actin riboprobes (200 pg) were coprecipitated with total RNA (3–5 µg) at a 100-fold molar excess of probe to target mRNAs and hybridized in 80% formamide hybridization buffer (RPAIII; Ambion) overnight at 42°C. Total RNA was isolated from dissected retinas using RNAzol B (Tel-test). Unhybridized probes were digested with an RNase A/RNase T1 mix (RPAIII; Ambion) and protected probes were precipitated with yeast carrier RNA (10 µg). Digestion of the polylinker sequence present in protected riboprobes generates shortened fragments: actin, 250 bp; ET-1, 484 bp; VEGF, 410 bp. Precipitated RNA fragments were resolved on a 7 M urea-5% polyacrylamide gel. Bands were visualized and quantitated by PhosphorImager analysis (Molecular Dynamics).
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Retinopathy of prematurity (ROP) is a vasoproliferative retinopathy of premature infants that results in severe visual impairment and blindness 12. Animal models that replicate clinical manifestations of ROP have been used to characterize the roles of vascular endothelial growth factor (VEGF 3456), VEGF receptors (flk-1 and flt-1 7), and hypoxia inducible factor-1 (HIF-1 8) in the pathogenesis of ROP. Exposure to hyperoxia results in the downregulation of VEGF production, vasoconstriction, cessation of retinal blood vessel growth, and loss of capillary beds 9. The vasoconstrictive response to hyperoxia has been proposed to be endothelin-1 (ET-1) dependent 10111213. The expression of ET mRNA in response to hyperoxia is unknown. The drop in retinal vessel density occurs via apoptosis and has been attributed to decreased levels of VEGF mRNA, as VEGF is required for the viability of vascular endothelial cells 45. The resulting nonperfused retinal tissue responds by increasing its VEGF production and new blood vessel growth 1415. VEGF-induced angiogenesis is Src dependent and Src kinase activity protects newly formed vessels from apoptosis 16.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Mice.
All mice were treated in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. c-Abl null mice were generated 31 and genotyped by PCR 32 as described previously. They were maintained in a 129Sv/Ev x C57Bl/6J hybrid background. Wt C57Bl/6 mice were purchased from Taconic Laboratories.
Oxygen-induced retinopathy was elicited in mice according to a previously established model 933. In brief, postnatal day 7 (P7) mice were exposed to 75% oxygen with their nursing mother for 5 d in an infant incubator (Ohmeda). On P12, animals were returned to normoxia and killed between P16 and P20 by lethal intraperitoneal injection of sodium pentobarbital. The greatest neovascular response occurs after P17 in this model 9. Age-matched animals were maintained in normoxia for the duration of the experiment.
Hydron pellets containing 250 ng VEGF (121 kD; R&D Systems) and sucralfate were prepared and surgically implanted into the mouse corneal stroma adjacent to the temporal limbus 35. Sham pellets were prepared using PBS instead of VEGF. 3-wk-old male and female mice that were +/+ or –/– for c-abl were used for pellet implantation. On day 7 after implantation, corneas were evaluated and photographed using slit lamp biomicroscopy.
The ET-1 cDNA fragment used to generate the ET-1 riboprobe contains 502 bp of the 5' coding region of the preproendothelin-1 cDNA (residues 426 to 928; reference 36). The fragment was obtained by PCR amplification of the Marathon mouse liver cDNA library (CLONTECH Laboratories, Inc.) using the Expanded High Fidelity PCR system (Boehringer) and synthetic oligonucleotide primers: 5' primer, 5'-AATTTCTGCCAAGCAGGAAAAGAAC; 3' primer, 5'-TCCTTCGAGTATGTTTTCAATT- TGT. The PCR product was digested with ApaI and XbaI and cloned into similarly digested pBluescript KS+ vector DNA (Stratagene). The VEGF cDNA fragment used to generate the VEGF riboprobe contains 411 bp of the 5' coding region that is common to murine VEGF-1, -2, and –3 cDNAs (residues 7–418; reference 37). The fragment was obtained by PCR amplification of the Marathon mouse liver cDNA library using the Expanded High Fidelity PCR system and synthetic oligonucleotide primers: 5' primer, 5' ATATGGATCCATGAACTTTCTGCTGTCTTGGGTG; 3' primer, 5' ATGAATTCTCCTGTCTTTCT- TTGGTCTGCATTC. The PCR product was TA cloned into pCRII-TOP0 (Invitrogen) followed by subcloning the Not1 and HindIII insert fragment into digested pBluescript KS+.
![]()
Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
c-Abl–deficient Mice Do Not Develop Retinal Neovascularization in Response to Hyperoxia.
To determine if mice deficient in c-abl are susceptible to hyperoxia-induced neovascularization, a mouse model for ROP was employed 9. Matings of mice that were heterozygous for the c-abl null allele were established to generate control and experimental age-matched litters 31. Control animals were maintained in room air (normoxia) for the duration of the experiment, and the experimental group was exposed to a hyperoxia regimen 5914. In this regimen, pups and their nursing mother were exposed to hyperoxia (75% oxygen) starting on P7 for 5 d followed by their return to normoxia on P12 for an additional 4–5 d. Retinas were harvested for examination of its vasculature by fluorescein angiography on P17–20. Animals that were wt (Fig. 1) or heterozygous (data not shown) for c-abl developed a strong vasoproliferative response to the hyperoxia treatment when compared with wt or c-abl heterozygous animals kept in normoxia. However, retinas of c-abl homozygous null mice exposed to hyperoxia exhibit minimal to no retinopathy when compared with retinas prepared from all mice maintained in normoxia (Fig. 1). This suggested that c-abl is required for hyperoxia-induced retinopathy to develop.
|
|
5) of neovascular nuclei were observed in retinas of mice (wt, +/–, and –/–) maintained in room air. The difference in the average numbers of nuclei between normoxia and hyperoxia-treated groups was significant (P < 0.001). In contrast, the mean number of nuclei counted in retinas of homozygous c-abl null mice exposed to hyperoxia was 5.5 as observed in normoxia control retinas. There is a significant difference (P < 0.002) in the means between homozygous (–/–) and control (+/+ and +/–) mice exposed to hyperoxia. The nuclei count data confirm the total retinopathy scoring values, demonstrating that the c-abl–deficient mice failed to develop hyperoxia-induced vasoproliferative retinopathy.
|
|
|
|
Exposure to Hyperoxia Does Not Elicit Decreased VEGF mRNA Expression in Retinas of c-abl–deficient Mice.
Because the homozygous null mice were protected from hyperoxia-induced retinal stress (Fig. 1Fig. 2Fig. 3), we sought to determine if differences in retinal VEGF mRNA expression among wt, heterozygous, and homozygous c-abl mice could be involved. Mice used for these experiments were of the hybrid strain. VEGF mRNA levels were assessed in P17 retinas of mice maintained in room air and of mice exposed to the hyperoxia regimen using RNase protection assays. VEGF mRNA expression in wt mice exposed to hyperoxia (Fig. 7, lanes 4 and 7) decreased sevenfold compared with the normoxia control level (Fig. 7, lane 3). In contrast, the VEGF mRNA levels in retinas of homozygous null animals exposed to the hyperoxia treatment remained consistently unchanged (Fig. 7, lanes 8 and 11) from levels observed in normoxia control retinas (Fig. 7, lanes 3 and 5). These data suggest that homozygous animals lacking any c-abl do not regulate VEGF mRNA expression in response to oxygen.
|
| Discussion |
|---|
|
|
|---|
Vasoconstriction of the central retinal vasculature has been described in animals treated with hyperoxia 912 and ET-1 activity has been implicated in retinal vasoconstriction 101113. Because it was unknown if hyperoxia induces altered ET-1 expression, we assessed retinal ET-1 mRNA levels in wt mice maintained in room air and exposed to the hyperoxia regimen. ET-1 mRNA levels remained constant in P6 and P17 retinas maintained in normoxia and did not change throughout the hyperoxia regimen. These data indicate that retinal ET-1 expression levels may not be regulated postnatally during retinal angiogenesis or change in response to increased levels of inspired oxygen. Nevertheless, a currently undefined role for constitutively expressed ET-1 may be important for normal retinal angiogenesis and vascular homeostasis.
To better understand why homozygous c-abl null mice were refractory to hyperoxia-induced stress as observed by their failure to develop a neovascular response to hyperoxia, we examined if VEGF-dependent signaling was aberrant in c-abl–deficient mice. A role for VEGF in oxygen-induced retinopathy has been documented by others 5714154041. Control and c-abl–deficient animals generated a robust neovascular response to VEGF-saturated corneal pellets indicating that c-abl is not necessary for VEGF-dependent signal transduction.
As the in vivo response to ectopically administered VEGF was intact in homozygous null mice, we analyzed VEGF mRNA expression. VEGF mRNA levels have been documented to be differentially regulated in the mouse model for ROP 51441. Others and we observed a fall in VEGF mRNA levels when C57Bl/6 mice were exposed to 75% oxygen, whereas a rise in levels occurred when animals were returned to normoxia. It has been proposed that the relative hypoxia experienced when animals are removed from 75% oxygen and placed in normoxia induces an accumulation of VEGF mRNA 4243. Also, we characterized the VEGF mRNA levels in our wt hybrid (129Sv/Ev x C57Bl/6J) mice throughout the hyperoxia regimen. The kinetics of VEGF mRNA expression induced by hyperoxia differed between wt C57Bl/5 and wt hybrid mice. The difference in gene regulation in response to oxygen among strains suggests that there may be multiple roles for VEGF in the development of oxygen-induced retinopathy. Recent results from the supplemental therapeutic oxygen for prethreshold (STOP)-ROP clinical trial in which supplemental oxygen therapy is administered to inhibit retinal neovascularization also raise the possibility that the role of VEGF in vasoproliferation is complex 2.
Because hyperoxia-induced retinopathy was not observed in c-abl–deficient mice and regulation of VEGF expression is important to the development of ROP, we determined whether c-abl knockout mice showed abnormal VEGF mRNA regulation when exposed to the hyperoxia regimen. Whereas hyperoxia-treated hybrid wt mice showed a large decrease in VEGF mRNA levels by P16, retinas of P16 hyperoxia-treated c-abl–deficient mice showed no such decrease. These data suggest that c-abl is required for the hyperoxia-induced downregulation of VEGF mRNA observed in the hybrid strain. Moreover, this observation implies that c-abl contributes to signal transduction pathways that regulate VEGF gene expression.
Taken together, our studies suggest that inhibition of c-abl activity may protect neonates from developing ROP. The therapeutic use of the c-abl tyrosine kinase inhibitor STI571 in the treatment of patients with chronic myelogenous leukemia has been shown to be promising 44. Experiments are currently underway to determine if administration of STI571 to wt mice can mimic the c-abl null phenotype and, thus, prevent the development of hyperoxia-induced retinopathy.
| Acknowledgments |
|---|
This work was support by grants from the National Eye Institute (K08 EY00373 to I. Nunes and K11 EY00330 to R.D. Higgins). S.P. Goff is an investigator of the Howard Hughes Institute.
Submitted: 5 September 2000
Revised: 13 April 2001
Accepted: 15 May 2001
| References |
|---|
|
|
|---|
Phelps D.L.. Retinopathy of prematurity, Pediatr. Rev., 16, 1995, 50–56.
Hay W.W.J. & Bell E.F.. Oxygen therapy, oxygen toxicity, and the STOP-ROP trial, Pediatrics, 105, 2000, 424–425.
Benjamin L.E., Hemo I. & Keshet E.. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF, Development, 125, 1998, 1591–1598.[Abstract]
Alon T., Hemo I., Itin A., Pe'er J., Stone J. & Keshet E.. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity, Nat. Med, 1, 1995, 1024–1028.[Medline]
Pierce E.A., Foley E.D. & Smith L.E.. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity, Arch. Ophthalmol, 114, 1996, 1219–1228[published erratum at 115:427].
Stone J., Itin A., Alon T., Pe'er J., Gnessin H., Chan-Ling T. & Keshet E.. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia, J. Neurosci, 15, 1995, 4738–4747.[Abstract]
Robbins S.G., Rajaratnam V.S. & Penn J.S.. Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina, Growth Factors, 16, 1998, 1–9.[Medline]
Ozaki H., Yu A.Y., Della N., Ozaki K., Luna J.D., Yamada H., Hackett S.F., Okamoto N., Zack D.J., Semenza G.L. & Campochiaro P.A.. Hypoxia inducible factor-1alpha is increased in ischemic retinatemporal and spatial correlation with VEGF expression, Invest. Ophthalmol. Vis. Sci, 40, 1999, 182–189.
Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R. & D'Amore P.A.. Oxygen-induced retinopathy in the mouse, Invest. Ophthalmol. Vis. Sci, 35, 1994, 101–111.
Brown S.M. & Jampol L.M.. New concepts of regulation of retinal vessel tone, Arch. Ophthalmol, 114, 1996, 199–204.
Murata M., Nakagawa M. & Takahashi S.. Selective expression of endothelin 1 mRNA in rat retina, Ophthalmologica, 212, 1998, 331–333.[Medline]
McLeod D.S., Brownstein R. & Lutty G.A.. Vaso-obliteration in the canine model of oxygen-induced retinopathy, Invest. Ophthalmol. Vis. Sci., 37, 1996, 2099–2109.
Takagi C., King G.L., Takagi H., Lin Y.W., Clermont A.C. & Bursell S.E.. Endothelin-1 action via endothelin receptors is a primary mechanism modulating retinal circulatory response to hyperoxia, Invest. Ophthalmol. Vis. Sci., 37, 1996, 2099–2109.
Pierce E.A., Avery R.L., Foley E.D., Aiello L.P. & Smith L.E.. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization, Proc. Natl. Acad. Sci. USA, 92, 1995, 905–909.
Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L. & Smith L.E.. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins, Proc. Natl. Acad. Sci. USA, 92, 1995, 10457–10461.
Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J. & Cheresh D.A.. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability, Mol. Cell, 4, 1999, 915–924.[Medline]
Kuroki M., Voest E.E., Amano S., Beerepoot L.V., Takashima S., Tolentino M., Kim R.Y., Rohan R.M., Colby K.A., Yeo K.T. & Adamis A.P.. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo, J. Clin. Invest, 98, 1996, 1667–1675.[Medline]
Penn J.S., Tolman B.L. & Bullard L.E.. Effect of a water-soluble vitamin E analog, trolox C, on retinal vascular development in an animal model of retinopathy of prematurity, Free Radic. Biol. Med, 22, 1997, 977–984.[Medline]
Rodriguez H., Drouin R., Holmquist G.P. & Akman S.A.. A hot spot for hydrogen peroxide-induced damage in the human hypoxia-inducible factor I binding site of the PGK 1 gene, Arch. Biochem. Biophys, 338, 1997, 207–212.[Medline]
Van Etten R.. Cycling, stressed-out and nervouscellular functions of c-Abl, Trends Cell Biol, 9, 1999, 179–186.[Medline]
Melo J. V.. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype, Blood, 88, 1996, 2375–2384.
Witte O.N.. Functions of the abl oncogene, Cancer Surv, 5, 1986, 183–197.[Medline]
Shaul Y.. c-ablactivation and nuclear targets, Cell Death Differ, 7, 2000, 10–16.[Medline]
Plattner R., Kadlec L., DeMali K.A., Kazlauskas A. & Pendergast A.M.. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF, Genes Dev, 13, 1999, 2400–2411.
Lewis J.M., Baskaran R., Taagepera S., Schwartz M.A. & Wang J.Y.. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport, Proc. Natl. Acad. Sci. USA, 93, 1996, 15174–15179.
Kharbanda S., Yuan Z.M., Weichselbaum R. & Kufe D.. Functional role for the c-Abl protein tyrosine kinase in the cellular response to genotoxic stress, Biochim. Biophys. Acta, 1333, 1997, 1–7.
Liu Z.G., Baskaran R., Lea-Chou E.T., Wood L.D., Chen Y., Karin M. & Wang J.Y.. Three distinct signalling responses by murine fibroblasts to genotoxic stress, Nature, 384, 1996, 273–276.[Medline]
Sun X., Majumder P., Shioya H., Wu F., Kumar S., Weichselbaum R., Kharbanda S. & Kufe D.. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species, J. Biol. Chem, 275, 2000, 17237–17240.
Sun X., Wu F., Datta R., Kharbanda S. & Kufe D.. Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress, J. Biol. Chem, 275, 2000, 7470–7473.
Simonson M.S., Wang Y. & Herman W.H.. Nuclear signaling by endothelin-1 requires Src protein-tyrosine kinases, J. Biol. Chem., 271, 1996, 77–82.
Tybulewicz V.L., Crawford C.E., Jackson P.K., Bronson R.T. & Mulligan R.C.. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene, Cell, 65, 1991, 1153–1163.[Medline]
Hardin J.D., Boast S., Mendelsohn M., de los Santos K. & Goff S.P.. Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice, Oncogene, 12, 1996, 2669–2677.[Medline]
Higgins R.D., Yu K., Sanders R.J., Nandgaonkar B.N., Rotschild T. & Rifkin D.B.. Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy, Curr. Eye Res, 18, 1999, 20–27.[Medline]
D'Amato R., Wesoloski E. & Smith L.E.. Microscopic visualization of the retina by angiography with high molecular-weight fluorescein-labeled dextrans in the mouse, Microvasc. Res., 46, 1993, 135–142.[Medline]
Kenyon B.M., Voest E.E., Chen C.C., Flynn E., Folkman J. & D'Amato R.J.. A model of angiogenesis in the mouse cornea, Invest. Ophthalmol. Vis. Sci, 37, 1996, 1625–1632.
Chan T.S., Lin C.X., Chan W.Y., Chung S.S. & Chung S.K.. Mouse preproendothelin-1 gene. cDNA cloning, sequence analysis and determination of sites of expression during embryonic development, Eur. J. Biochem., 234, 1995, 819–826.[Medline]
Breier G., Albrecht U., Sterrer S. & Risau W.. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation, Development, 114, 1992, 521–532.[Abstract]
Provis J.M., Leech J., Diaz C.M., Penfold P.L., Stone J. & Keshet E.. Development of the human retinal vasculaturecellular relations and VEGF expression, Exp. Eye Res, 65, 1997, 555–568.[Medline]
Stone J., Chan-Ling T., Pe'er J., Itin A., Gnessin H. & Keshet E.. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity, Invest. Ophthalmol. Vis. Sci, 37, 1996, 290–299.
Smith L.E., Shen W., Perruzzi C., Soker S., Kinose F., Xu X., Robinson G., Driver S., Bischoff J. & Zhang B.. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor, Nat. Med, 5, 1999, 1390–1395.[Medline]
Donahue M.L., Phelps D.L., Watkins R.H., LoMonaco M.B. & Horowitz S.. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy, Curr. Eye Res, 15, 1996, 175–184.[Medline]
Aiello L.P., Northrup J.M., Keyt B.A., Takagi H. & Iwamoto M.A.. Hypoxic regulation of vascular endothelial growth factor in retinal cells, Arch. Ophthalmol, 113, 1995, 1538–1544.
Stein I., Neeman M., Shweiki D., Itin A. & Keshet E.. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes, Mol. Cell. Biol, 15, 1995, 5363–5368.[Abstract]
Druker B.J. & Lydon N.B.. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia, J. Clin. Invest, 105, 2000, 3–7.[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|